Skip to main content
SHANGHAI ALLIST PHARMACEUTICALS CO., LTD logo

SHANGHAI ALLIST PHARMACEUTICALS CO., LTD — Investor Relations & Filings

Ticker · 688578 ISIN · CNE100005XJ7 Shanghai Stock Exchange Manufacturing
Filings indexed 450 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688578

About SHANGHAI ALLIST PHARMACEUTICALS CO., LTD

https://www.allist.com.cn/

Shanghai Allist Pharmaceuticals Co., Ltd. focuses on the discovery, development, and commercialization of innovative oncology therapeutics. The company specializes in small molecule targeted therapies, primarily addressing unmet medical needs in the treatment of non-small cell lung cancer (NSCLC). Its lead product, furmonertinib, is a third-generation EGFR tyrosine kinase inhibitor (TKI) indicated for patients with specific genetic mutations. Allist operates an integrated R&D and manufacturing platform, advancing a pipeline of candidates designed to target various oncogenic drivers. The company aims to deliver precision medicine solutions through its expertise in molecular design and clinical development.

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.